Literature DB >> 11020254

Comparison of the in vitro activities of rifapentine and rifampicin against Mycobacterium tuberculosis complex.

P Bemer-Melchior1, A Bryskier, H B Drugeon.   

Abstract

The in vitro activity of rifapentine for 44 clinical isolates of Mycobacterium tuberculosis complex was compared with that of rifampicin using the Bactec radiometric method and the absolute concentration method for susceptibility testing. Twenty-nine M. tuberculosis, 11 Mycobacterium bovis and four Mycobacterium africanum strains were studied. Control tests showed that rifapentine was stable for 14 days in 7H9 broth and for 3 weeks in 7H10 agar medium. The 44 M. tuberculosis complex strains were more susceptible to rifapentine than to rifampicin, irrespective of the testing method. In the radiometric system, the MIC50 and MIC90 of rifapentine for M. tuberculosis complex strains were one or two two-fold dilutions lower than those of rifampicin (0.06-0.125 mg/L versus 0.25 mg/L, respectively). By the absolute concentration method, the MIC50 and MIC90 of rifapentine for M. tuberculosis complex strains were two two-fold dilutions lower than those of rifampicin (0.125-0.25 mg/L versus 0.5-1 mg/L, respectively). The MIC90 of rifapentine for the 44 M. tuberculosis complex strains was always 0.25 mg/L, irrespective of the method used, but the radiometric method was more reliable and more reproducible than the agar 7H10 method.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11020254     DOI: 10.1093/jac/46.4.571

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  19 in total

1.  New regimens for reducing the duration of the treatment of drug-susceptible pulmonary tuberculosis.

Authors:  Marcus B Conde; José R Lapa E Silva
Journal:  Drug Dev Res       Date:  2011-09       Impact factor: 4.360

Review 2.  New drugs against tuberculosis: problems, progress, and evaluation of agents in clinical development.

Authors:  Jossy van den Boogaard; Gibson S Kibiki; Elton R Kisanga; Martin J Boeree; Rob E Aarnoutse
Journal:  Antimicrob Agents Chemother       Date:  2008-12-15       Impact factor: 5.191

Review 3.  New antituberculous drugs derived from natural products: current perspectives and issues in antituberculous drug development.

Authors:  Masayuki Igarashi; Yoshimasa Ishizaki; Yoshiaki Takahashi
Journal:  J Antibiot (Tokyo)       Date:  2017-11-01       Impact factor: 2.649

4.  High-dose rifapentine with or without moxifloxacin for shortening treatment of pulmonary tuberculosis: Study protocol for TBTC study 31/ACTG A5349 phase 3 clinical trial.

Authors:  Susan E Dorman; Payam Nahid; Ekaterina V Kurbatova; Stefan V Goldberg; Lorna Bozeman; William J Burman; Kwok-Chiu Chang; Michael Chen; Mark Cotton; Kelly E Dooley; Melissa Engle; Pei-Jean Feng; Courtney V Fletcher; Phan Ha; Charles M Heilig; John L Johnson; Erica Lessem; Beverly Metchock; Jose M Miro; Nguyen Viet Nhung; April C Pettit; Patrick P J Phillips; Anthony T Podany; Anne E Purfield; Kathleen Robergeau; Wadzanai Samaneka; Nigel A Scott; Erin Sizemore; Andrew Vernon; Marc Weiner; Susan Swindells; Richard E Chaisson
Journal:  Contemp Clin Trials       Date:  2020-01-22       Impact factor: 2.226

5.  Higher Dosing of Rifamycins Does Not Increase Activity against Mycobacterium tuberculosis in the Hollow-Fiber Infection Model.

Authors:  E D Pieterman; S van den Berg; A van der Meijden; E M Svensson; H I Bax; J E M de Steenwinkel
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

6.  Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers.

Authors:  K E Dooley; E E Bliven-Sizemore; M Weiner; Y Lu; E L Nuermberger; W C Hubbard; E J Fuchs; M T Melia; W J Burman; S E Dorman
Journal:  Clin Pharmacol Ther       Date:  2012-05       Impact factor: 6.875

7.  In vitro comparison of three rifampicin loading methods in a reinforced porous β-tricalcium phosphate scaffold.

Authors:  Junjie Yuan; Baoxin Wang; Chen Han; Xiao Lu; Wei Sun; Dezhi Wang; Jianxi Lu; Jie Zhao; Chao Zhang; Youzhuan Xie
Journal:  J Mater Sci Mater Med       Date:  2015-03-28       Impact factor: 3.896

8.  Bis-spirochromanones as potent inhibitors of Mycobacterium tuberculosis: synthesis and biological evaluation.

Authors:  Ashok Dongamanti; Vikas Kumar Aamate; Mohan Gandhi Devulapally; Srinivas Gundu; Saikrishna Balabadra; Vijjulatha Manga; Perumal Yogeeswari; Dharmarajan Sriram; Sridhar Balasubramanian
Journal:  Mol Divers       Date:  2017-08-24       Impact factor: 2.943

9.  Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial.

Authors:  Susan E Dorman; Radojka M Savic; Stefan Goldberg; Jason E Stout; Neil Schluger; Grace Muzanyi; John L Johnson; Payam Nahid; Emily J Hecker; Charles M Heilig; Lorna Bozeman; Pei-Jean I Feng; Ruth N Moro; William MacKenzie; Kelly E Dooley; Eric L Nuermberger; Andrew Vernon; Marc Weiner
Journal:  Am J Respir Crit Care Med       Date:  2015-02-01       Impact factor: 21.405

10.  Cationic antimicrobial peptides and biogenic silver nanoparticles kill mycobacteria without eliciting DNA damage and cytotoxicity in mouse macrophages.

Authors:  Soumitra Mohanty; Prajna Jena; Ranjit Mehta; Rashmirekha Pati; Birendranath Banerjee; Satish Patil; Avinash Sonawane
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.